A
Applied Genetics Technologies Corporation
Biotechnology company conducting human clinical trials of aav-based gene therapies for the treatment of rare diseases
About Applied Genetics Technologies Corporation
Applied Genetics Technologies Corporation (AGTC), established in 1999, operated as a clinical-stage biotechnology company focused on developing gene therapies for rare and debilitating diseases. The company was acquired by Syncona in the fourth quarter of 2022 and now operates as a portfolio company, with its stock no longer publicly traded. The acquisition was valued at approximately $23.5 million upfront, with potential for an additional $50 million based on future milestones.
AGTC's business model revolved around its proprietary gene therapy platform, which utilizes adeno-associated virus (AAV) vectors to deliver functional genes to correct genetic defects. The company's primary focus was on inherited retinal diseases with high unmet medical needs, such as X-linked Retinitis Pigmentosa (XLRP) and Achromatopsia (ACHM). Prior to its acquisition, AGTC's strategy involved advancing its product candidates through clinical trials to gain regulatory approval and eventual commercialization, generating revenue through partnerships, and potentially, future product sales. A significant collaboration was established with Biogen in 2015 to develop gene-based therapies for several ophthalmic diseases, which included a $124 million upfront payment to AGTC.
The company's lead product candidate is AGTC-501 (laruparetigene zosaparvovec), a gene therapy for XLRP, a genetic eye disease that causes progressive vision loss in males. This therapy is designed to deliver a full-length version of the RPGR gene to address both rod and cone photoreceptor damage. Post-acquisition, under Beacon Therapeutics (another Syncona company), AGTC-501 has continued to show promise. As of October 2024, 24-month data from the Phase 2 SKYLINE trial showed a 57% response rate in improving retinal sensitivity in the high-dose group, with a favorable safety profile. The therapy is advancing to late-stage trials, with the Phase 2/3 VISTA trial currently enrolling patients. AGTC also developed candidates for achromatopsia, with AGTC-401 for CNGB3 mutations showing some positive activity, while the program for CNGA3 mutations (AGTC-402) was discontinued due to lack of clinical improvement.
Sue Washer served as the President and CEO for 17 years, leading the company from a university spin-out to a publicly traded entity before its acquisition. Her background combines a biochemistry degree with an MBA from the University of Florida, bridging the gap between science and business from her time at Abbott Labs and Eli Lilly. She was instrumental in securing significant investments, navigating the company through clinical milestones, and negotiating key partnerships.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Alachua, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
News
Open roles
Applied Genetics Technologies Corporation in the Alachua ecosystem
The Applied Genetics Technologies Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
MedImmune Ventures
Intersouth Partners
InterWest Partners
Skyline VenturesSR One
Alta Partners- APAlta Capital Partners
Osage University Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Applied Genetics Technologies Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Applied Genetics Technologies Corporation on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


